Maharashtra FDA Withdraws Cipla Pune Licence Cancellation After Bombay High Court Challenge

Finin2min 2-minute summary

The Maharashtra Food and Drug Administration’s cancellation of the drug-sale licence of Cipla Pharma & Life Sciences’ carrying-and-forwarding unit at Wadki, Pune did not remain in force. After Cipla approached the Bombay High Court, the FDA withdrew the cancellation and said it would issue a fresh show-cause notice and pass a reasoned decision after considering the company’s response. The Court reportedly criticised the procedure followed in the earlier action. The correct current status is therefore withdrawal of the cancellation order with regulatory proceedings capable of restarting—not a permanent licence cancellation and not a final exoneration on the underlying allegations.

What triggered the FDA action

The original FDA action concerned alleged irregularities involving Reactin Plus, a Schedule H prescription medicine, along with storage, record-keeping and recall practices at the C&F facility. Reports said the regulator questioned packaging language, seized stock it treated as misbranded and later alleged that recall directions were not fully complied with. It also cited differences between physical and computerised stock records and storage deficiencies. Cipla said the order did not allege any issue with the safety, quality or efficacy of its products.

Why the High Court intervention matters

Regulatory enforcement must follow the procedure required by law and basic principles of natural justice. Cipla’s challenge focused on the hearing process, including the timing of a proposed hearing on a public holiday and the subsequent cancellation. The FDA’s decision to withdraw the order and start afresh means the process will have to give the company a proper opportunity to respond before a new reasoned decision. Procedural correction does not erase the underlying inspection record.

Compliance lesson for pharma distribution

A C&F facility may not manufacture the medicine, but it sits inside the regulated supply chain. Storage conditions, stock reconciliation, recall execution, expired-product handling and documentation can all affect the licence. Companies should therefore audit distribution nodes with the same seriousness as manufacturing sites. A recall instruction is especially sensitive because incomplete execution can create both regulatory and reputational exposure.

Finance and disclosure lens

A temporary regulatory restriction can affect inventory movement, distribution continuity and working capital even if it is later withdrawn. Listed-company finance teams should assess materiality based on the affected facility, product flows and duration rather than simply the existence of a notice. Public disclosure should also reflect current legal status. Continuing to describe a withdrawn order as operative can mislead investors just as much as ignoring the original action.

Legal-status discipline

There are now at least three distinct stages: the FDA’s original allegations and cancellation, Cipla’s legal challenge, and withdrawal with a fresh process promised. A future show-cause notice would be another stage, and a later final order could reach a different outcome. Finin2min’s editorial approach is to state each status precisely rather than compress them into “Cipla wins” or “FDA bans Cipla” headlines.

What to watch next

Watch the fresh show-cause notice, Cipla’s response and the reasoned FDA order that follows. If an official Bombay High Court order is released, Finin2min should attach it to the source trail and update the legal analysis. For compliance teams across pharma distribution, the immediate takeaway is two-sided: fix documentary and operational gaps early, and insist that enforcement proceedings also comply with due process.

Primary source

India Today / reported Bombay High Court proceedings — Bombay High Court proceedings reported 29 August 2026.

For information and education only. This is not investment, tax, legal or accounting advice.